Plasma Metabolomics Profile of "Insulin Sensitive" Male Hypogonadism after Testosterone Replacement Therapy

被引:6
|
作者
Zolla, Lello [1 ]
Ceci, Marcello [1 ]
机构
[1] Univ Tuscia, Dept Ecol & Biol Sci DEB, I-00110 Viterbo, Italy
关键词
insulin sensitivity; hypogonadism; testosterone therapy; Cori cycle; GLUCOSE-METABOLISM; MITOCHONDRIAL BIOGENESIS; MEN; DEFICIENCY; MUSCLE; SUPPLEMENTATION; GLUTAMINOLYSIS; METAANALYSIS; DYSFUNCTION; MANAGEMENT;
D O I
10.3390/ijms23031916
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Male hypogonadism is a disorder characterized by low levels of testosterone, but patients can either show normal insulin (insulin-sensitive (IS)) or over time they can become insulin-resistant (IR). Since the two groups showed different altered metabolisms, testosterone replacement therapy (TRT) could achieve different results. In this paper, we analyzed plasma from 20 IS patients with low testosterone (<8 nmol/L) and HOMAi < 2.5. The samples, pre- and post-treatment with testosterone for 60 days, were analyzed by UHPLC and mass spectrometry. Glycolysis was significantly upregulated, suggesting an improved glucose utilization. Conversely, the pentose phosphate pathway was reduced, while the Krebs cycle was not used. Branched amino acids and carnosine metabolism were positively influenced, while beta-oxidation of fatty acids (FFA) was not activated. Cholesterol, HDL, and lipid metabolism did not show any improvements at 60 days but did so later in the experimental period. Finally, both malate and glycerol shuttle were reduced. As a result, both NADH and ATP were significantly lower. Interestingly, a significant production of lactate was observed, which induced the activation of the Cori cycle between the liver and muscles, which became the main source of energy for these patients without involving alanine. Thus, the treatment must be integrated with chemicals which are not restored in order to reactivate energy production.
引用
收藏
页数:14
相关论文
共 50 条
  • [1] Testosterone replacement therapy in male hypogonadism
    Byrne, MM
    Nieschlag, E
    JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2003, 26 (05) : 481 - 489
  • [2] Testosterone Replacement Therapy for Male Hypogonadism
    Heidelbaugh, Joel J.
    Belakovskiy, Aleksandr
    AMERICAN FAMILY PHYSICIAN, 2024, 109 (06) : 543 - 549
  • [3] Testosterone replacement therapy in male hypogonadism
    M. M. Byrne
    E. Nieschlag
    Journal of Endocrinological Investigation, 2003, 26 : 481 - 489
  • [4] Bone benefits of testosterone replacement therapy in male hypogonadism
    Tirabassi, G.
    Biagioli, A.
    Balercia, G.
    PANMINERVA MEDICA, 2014, 56 (02) : 151 - 163
  • [5] How to prescribe: Testosterone replacement therapy in male hypogonadism
    Lacarriere, E.
    PROGRES EN UROLOGIE, 2015, 25 (01): : F16 - F18
  • [6] Testosterone replacement in male hypogonadism
    Kalra, Sanjay
    Agrawal, Navneet
    Kumar, Satish
    Sharma, Amit
    CLINICAL PHARMACOLOGY-ADVANCES AND APPLICATIONS, 2010, 2 : 149 - 153
  • [7] Society for Endocrinology guidelines for testosterone replacement therapy in male hypogonadism
    Jayasena, Channa
    Anderson, Richard A.
    Llahana, Sofia
    Barth, Julian
    MacKenzie, Finlay
    Wilkes, Scott
    Smith, Neil D.
    Sooriakumaran, Prasanna
    Minhas, Suks
    Wu, Frederick C. W.
    Tomlinson, Jeremy W.
    Quinton, Richard
    CLINICAL ENDOCRINOLOGY, 2022, 96 (02) : 200 - 219
  • [8] Hypogonadism - Testosterone Replacement Therapy after Prostate Carcinoma?
    van Essen, Julius
    Pfister, David
    Heidenreich, Axel
    AKTUELLE UROLOGIE, 2014, 45 (01) : 17 - 18
  • [9] Hypogonadism in the Aging Male Diagnosis, Potential Benefits, and Risks of Testosterone Replacement Therapy
    Surampudi, Prasanth N.
    Wang, Christina
    Swerdloff, Ronald
    INTERNATIONAL JOURNAL OF ENDOCRINOLOGY, 2012, 2012
  • [10] Late-onset male hypogonadism and testosterone replacement therapy in primary care
    Brunton, Stephen A.
    Sadovsky, Richard
    JOURNAL OF FAMILY PRACTICE, 2010, 59 (07):